John Stageman Ph.d.

Biography

Dr. John Stageman is the Head of Interim Site and Vice President at MedImmune Inc. He holds this position since December 20, 2007. Dr. Stageman has nearly 30 years of experience in R&D management throughout AstraZeneca (AZ) and its predecessor companies, having pioneered large-scale biotechnology process development and scale-up at the start of his career. Initially trained as a Physical and Colloid Chemist, he led the Biopharmaceutical Strategy Team that motivated AZ’s aggressive drive into biological drugs including the acquisition of both Cambridge Antibody Technology (CAT) and MedImmune, being a Vice President at AZ. Dr. Stageman entered the pharmaceutical business in 1993 rising through a number of senior roles in both drug discovery and development project management. In 1996, he led the team that initiated the successful Phase 3 development of Faslodex(R) (fulvestrant). Dr. Stageman is a Member of the Strategic Advisory Board at UMIP Premier Fund. He is an Honorary Professor at the University of Manchester and a member of the North West Science Council. He has recently been appointed to the Biotechnology & Biological Sciences Research Council and was previously a member of the Royal Society Working Party on Pharmacogenetics. Dr. Stageman has served on several United Kingdom Research Council grant committees. He holds both a Doctorate in Physical Chemistry from the University of Bristol and B.S. degree in Chemistry from the same university.

Research Interest

Oncology